SynthesisBMC gastroenterology2025
Prognostic value of the platelet-to-lymphocyte ratio in colorectal cancer patients undergoing chemotherapy: a systematic review and meta-analysis.
Synthesis in BMC gastroenterology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Beyond the biopsy: the new era of non-invasive staging and biomarkers in colorectal cancer.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026Review
- Retrospective analysis of the occurrence pattern of complications and prognostic influencing factors in elderly patients with squamous cell lung cancer after radical surgery.World journal of surgical oncology · 2026Article
- Longitudinal Assessment of Hematologic and Immunonutritional Biomarkers from Treatment Initiation to Progression in Metastatic Colorectal Cancer.Biomedicines · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThis research aimed to estimate the prognostic value of the platelet-to-lymphocyte ratio (PLR) in colorectal cancer (CRC) patients receiving chemotherapy.
methodsEmbase, the Cochrane Library, Web of Science, and PubMed were searched from inception to March 20, 2025. Pooled hazard ratios (HRs) with 95% confidence intervals (CIs) were calculated to appraise the predictive significance of PLR among CRC patients receiving chemotherapy. The robustness of the findings and potential publication bias were assessed by sensitivity analysis and Egger's test, respectively. The impact of confounding variables was investigated through subgroup and regression analyses.
resultsIn total, 33 studies involving 7,529 individuals were included. Statistical analysis of categorical variables demonstrated that an increased PLR was significantly related to overall survival (OS) (HR = 1.33, 95% CI = 1.14-1.54), progression-free survival (PFS) (HR = 1.32, 95% CI = 1.06-1.63), and relapse-free survival (RFS) (HR = 1.77, 95% CI = 1.13-2.77) in CRC patients receiving chemotherapy, whereas no significant relationship was found with disease-free survival (DFS) (HR = 1.19, 95% CI = 0.84-1.69). Subgroup analyses indicated that, among metastatic CRC patients, a higher PLR was significantly linked to unfavorable OS and DFS. In CRC patients receiving adjuvant chemotherapy or chemotherapy with or without targeted therapy, high PLR was significantly related to worse OS and PFS.
conclusionAn elevated PLR is related to adverse prognosis among CRC patients undergoing chemotherapy. In clinical practice, PLR may be a promising and cost-effective predictive marker for this population.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.